AstraZeneca’s hopes of extending the uses of its blockbuster drug Seroquel in the US have met with a mixed response from a key panel of medical experts.

The extended release form of Seroquel is currently approved in the US for the treatment of schizophrenia and bipolar disorder. Global sales of Seroquel were $4.5bn last year, making it AstraZeneca’s second biggest selling drug.